Effect of buflomedil on behaviour, memory, and intellectual capacity in patients with dementia. A placebo-controlled study.
A double-blind, placebo-controlled clinical study of the efficacy and safety of buflomedil in the treatment of dementia was conducted in 55 patients. A statistically significant improvement was achieved for such characteristics as mood, self-care, alertness, emotional lability, indifference, hostility, and anxiety. Compared with placebo, buflomedil showed a clear superiority with regard to improvement in cognitive dysfunction and psychosomatic dysfunction, with a trend toward statistical significance in improvement in interpersonal relations. Secondary analysis of a subset of patients without evidence of earlier cerebrovascular accident showed similar clinical responses and statistical findings. Buflomedil was well tolerated.
D000342:Affective Symptoms / Q000188:drug therapy; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000188:drug therapy; D003704:Dementia / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007360:Intelligence / Q000187:drug effects; D007398:Interpersonal Relations; D008297:Male; D008568:Memory / Q000187:drug effects; D008875:Middle Aged; D010919:Placebos; D011759:Pyrrolidines / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
D010919:Placebos; D011759:Pyrrolidines; D014665:Vasodilator Agents; C010651:buflomedil